Savara (SVRA) Amortizatization of Intangibles (2012 - 2026)
Savara's (SVRA) quarterly Amortizatization of Intangibles came in at $565000.0 in Q1 2026, down 50.83% year-on-year from $1.1 million in Q1 2025, and up 15.31% on a QoQ basis from $490000.0 in Q4 2025.
Savara (SVRA) Amortizatization of Intangibles (2012 - 2026) Analysis & Trends
Savara (SVRA) has 8 years of Amortizatization of Intangibles data on file, last reported at $565000.0 in Q1 2026.
- On a quarterly basis, Amortizatization of Intangibles fell 50.83% year-over-year to $565000.0 in Q1 2026; TTM through Mar 2026 was $2.3 million, a 56.29% decrease from a year earlier, with the FY2025 full-year figure at $2.9 million, down 47.34% from the prior year.
- Amortizatization of Intangibles for Q1 2026 stood at $565000.0, up from $490000.0 in the prior quarter.
- Over the last five years, Amortizatization of Intangibles for SVRA reached as high as $1.6 million in Q4 2023 and fell as low as -$267000.0 in Q1 2022.
- Historically, Amortizatization of Intangibles has averaged $810705.9 across 5 years, with a median of $913000.0 in 2023.
- Across the five-year window, Amortizatization of Intangibles jumped 2572.13% in 2023 and plunged 71.16% in 2025, its largest moves.
- Year by year, Amortizatization of Intangibles stood at $357000.0 in 2022, then surged by 359.1% to $1.6 million in 2023, then declined by 10.31% to $1.5 million in 2024, then slumped by 66.67% to $490000.0 in 2025, then gained by 15.31% to $565000.0 in 2026.
- Per Business Quant data, the three most recent Amortizatization of Intangibles figures were $565000.0 in Q1 2026, $490000.0 in Q4 2025, and $426000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 3.22 Mn |
| 10 | Savara | 1.39 Bn | 1.39 Bn | - | 565,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 565,000.00 |
| Mar 31, 2026 | 565,000.00 |
| Dec 31, 2025 | 490,000.00 |
| Dec 31, 2025 | 490,000.00 |
| Sep 30, 2025 | 426,000.00 |
| Sep 30, 2025 | 426,000.00 |
| Jun 30, 2025 | 801,000.00 |
| Jun 30, 2025 | 801,000.00 |
| Mar 31, 2025 | 1.15 Mn |
| Mar 31, 2025 | 1.15 Mn |
| Dec 31, 2024 | 1.47 Mn |
| Dec 31, 2024 | 1.47 Mn |
| Sep 30, 2024 | 1.48 Mn |
| Sep 30, 2024 | 1.48 Mn |
| Jun 30, 2024 | 1.13 Mn |
| Jun 30, 2024 | 1.13 Mn |
| Mar 31, 2024 | 1.37 Mn |
| Mar 31, 2024 | 1.37 Mn |
| Dec 31, 2023 | 1.64 Mn |
| Dec 31, 2023 | 1.64 Mn |